



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/776,837
Filing Date	February 11, 2004
First Named Inventor	Byung H. Lee, et al.
Art Unit	1625
Examiner Name	not available yet
Attorney Docket Number	01453.US1

Total Number of Pages in This Submission

**ENCLOSURES (Check all that apply)**

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br><input type="checkbox"/> Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):<br>A return-receipt postcard is enclosed.<br>References |
|--|--|---|

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Pharmacia & Upjohn Company, John H. Engelmann (28,075)
Signature	John H. Engelmann
Date	MAY 5, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Julie K. Lyons
-----------------------	----------------

Signature

Julie K. Lyons

Date

May 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>				Atty. Docket No.		Serial No.	
				01453.US1		10/776,837	
				Applicants Byung H. Lee, et al.			
				Filing Date 2/11/2004		1625	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,498,720	March 12, 1996	Lee	546	276	
	AB	5,489,598	Feb. 6, 1996	Connor et al.	514	384	
	AC	4,481,360	Nov. 6, 1984	Gall et al.	546	210	
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
	AD	WO 01/31005	May 3, 2001	WIPO	C12N	15/12	
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AI	T. G. Shevchenko Kiev State University, Kiev 252017 pp. 914-917. Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 8, pp. 1132-1134, August 1977. Original article submitted July 8, 1976.					
	AJ	Berge et al., J. Miami. Sci., 66:1-19 (1977)					
	AK	Birgul et al., The EMBO J., 18 5892-5900 (1999)					
	AL	N. Bodor, "Novel Approaches in Prodrug Design," Drugs of the Future, 6(3):165-182 (1981)					
	AM	J. W. Bowman, et al., J. of Neurophys., 74(5), 1880-1888 (1995)					
	AN	H. Bundgaard, "Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities," in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, N.Y. (1985)					
	AO	R. E. Davis, et al., J. of Neurosci., 9(2), 403-414 (1989)					
	AP	N. N. Gulermann, et al., Il Farmaco 56(12), 953-958 (2001)					
	AQ	R. K. Jaiswal, et al., J. Heterocycle. Chem., 16, 561-565 (1979)					
	AR	M. J. Larsen, et al., Biochemical and Biophysical Research Communications, 286, 895-901 (2001)					
	AS	Lee, op.cit. E. G. Knish, et al., Farmatsevtichnii Zhurnal 2, 64-65 (1983) and translation, "Synthesis, Properties and Biological activity of 5-Acylalkylmercapto-1,2, 4-Triazoles" Zaporozhe Medical Institute (UDC)					
	AT	Lenz et al., Biochem. Biophys. Res. Comm. 273, 1126-1131 (2000)					
	AU	R. Nichols, J. Neurogenetics, 16, 1-28 (2002)					
	AV	R.E. Notari, "Theory and Practice of Prodrug Kinetics," Methods in Enzymology, 112:309-323 (1985)					
Examiner				Date Considered			